Opening its latest reports…Reading every line of the four statements…Putting it into plain words…
REGNRegeneron Pharmaceuticals, Inc.
The four financial statements
Every company that sells shares in the US files four statements with the SEC. Together they show whether Regeneron Pharmaceuticals made money, what it owns and owes, where its cash went, and what changed for its shareholders. Below is every line exactly as Regeneron Pharmaceuticals filed it, with what each one means in plain English.
As filed with the SEC on Feb 4, 2026 · the full report · SEC's figures viewer
Income statement · also called the statement of operations, statement of earnings or profit and loss
Did it make money?
Read it from the top down. It starts with everything customers paid (sales), takes away the cost of making what was sold, then the costs of running the company, then interest and tax. What is left at the bottom is profit (net income), the part that belongs to shareholders. It covers a stretch of time: a year, or a quarter.
- People usually check: Are sales growing compared with a year earlier?
- People usually check: How much of each dollar of sales is left at each step (the margins)?
- People usually check: Is profit growing faster or slower than sales?
Point at or tap a bar to see the lines inside it.
Out of every $100 of sales
- costs of running the business: $75
- other income and costs: $12 added
- income tax: $5
- kept as profit: $31.4
Every line, explained
| Line (tap for what it means) | 12 months to Dec 31, 2025 | 12 months to Dec 31, 2024 | 12 months to Dec 31, 2023 |
|---|---|---|---|
| Revenues | |||
| $14.3B▲ 1.0% | $14.2B | $13.1B | |
| Expenses | |||
| $5.9B▲ 14% | $5.1B | $4.4B | |
| $124.1M▲ 23% | $101.0M | $186.1M | |
| $2.7B▼ 8.6% | $3.0B | $2.6B | |
| −$10.0M | $53.4M | −$2.1M | |
| $10.8B▲ 5.4% | $10.2B | $9.1B | |
| $3.6B▼ 10% | $4.0B | $4.0B | |
| Other income (expense) | |||
| $1.7B▲ 101% | $844.4M | $225.2M | |
| −$43.8M▲ 21% | −$55.2M | −$73.0M | |
| $1.7B▲ 109% | $789.2M | $152.2M | |
| $5.2B▲ 9.4% | $4.8B | $4.2B | |
| $725.8M▲ 98% | $367.3M | $245.7M | |
| $4.5B▲ 2.1% | $4.4B | $4.0B | |
| $43.07▲ 5.3% | $40.90 | $37.05 | |
| $41.48▲ 8.2% | $38.34 | $34.77 | |
| 104.6M shares▼ 3.1% | 107.9M shares | 106.7M shares | |
| 108.6M shares▼ 5.6% | 115.1M shares | 113.7M shares | |
| Statements of Comprehensive Income | |||
| $4.5B▲ 2.1% | $4.4B | $4.0B | |
| Other comprehensive income (loss), net of tax | |||
| $83.0M▲ 13% | $73.6M | $158.2M | |
| $2.4M | −$600.0K | −$300.0K | |
| $4.6B▲ 2.3% | $4.5B | $4.1B | |
Split by Net product sales, Collaboration revenue, Other revenue, Cost of collaboration and contract manufacturing
| Net product sales | |||
|---|---|---|---|
| Sales (Revenue from contract with customer) | $6.3B | $7.6B | $7.1B |
| Cost of making what it sold (Cost of goods sold and of collaboration and contract manufacturing) | $1.1B | $1.1B | $932.1M |
| Collaboration revenue | |||
| Sales (Revenue from contract with customer) | $7.3B | $6.1B | $5.5B |
| Other revenue | |||
| Sales (Revenue from contract with customer) | $702.6M | $515.0M | $536.1M |
| Cost of collaboration and contract manufacturing | |||
| Cost of making what it sold (Cost of goods sold and of collaboration and contract manufacturing) | $959.9M | $883.2M | $883.7M |
Every line as the company filed it (USD ($), shares in Millions, $ in Millions), shown in full dollars. See this statement on SEC.